HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (16) Citing Articles via Google Scholar Google Scholar Articles by West, J. Articles by Rodman, D. M. Search for Related Content PubMed PubMed Citation Articles by West, J. Articles by Rodman, D. M.

Gene Therapy for Pulmonary Diseases^*

^* From the Department of Medicine, University of Colorado Health Sciences Center, Denver, CO.

Correspondence to: David M. Rodman, MD, 4200 E. Ninth Ave, Box B-133, Denver, CO 80262; e-mail: david.rodman{at}uchsc.edu

Abstract

Gene therapy for pulmonary disease has attracted a great deal of attention since the first report of successful gene delivery 10 years ago. Potential indications for gene therapy include chronic illnesses such as cystic fibrosis and ₁-antitrypsin deficiency, and acute illnesses such as acute transplant rejection and chemotherapy-induced lung injury. The key technological impediment to successful gene therapy is vector optimization. Viral vectors, including adenovirus and adeno-associated virus, have relatively low efficiency in vivo. In addition, adenovirus has been associated with a brisk inflammatory response and limited duration of expression in the lung. Nonviral vectors, particularly liposomes, have also been tried, with limited expression efficiency and some toxicity. Although work is ongoing to improve adenoviral and adeno-associated viral vectors and test other viral and nonviral vectors, an ideal vector has not yet been identified. Several important barriers to successful gene therapy, including the host inflammatory response, promotor down-regulation, tissue-specific targeting, and physical barriers to gene delivery in the airway, will need to be overcome. Despite these daunting problems, several human gene therapy trials have been completed, using adenovirus, adeno-associated virus, and liposomes. In general, these trials have been focused on safety, and have shown that there is dose-dependent inflammation in response to adenovirus. Adeno-associated virus appears to cause little inflammation. Demonstration of successful gene delivery and transcription has been quite variable in human trials. In general, the level of expression of transgene appears to be quite low. In summary, although there is great promise for gene therapy in the lung, significant challenges remain in translating this technology to successful human therapy.

Key Words: adeno-associated virus • adenovirus • DNA • inflammation • plasmid • vector • virus

This article has been cited by other articles:

				Y. Wang, Y. Manevich, S. I. Feinstein, and A. B. Fisher Adenovirus-mediated transfer of the 1-cys peroxiredoxin gene to mouse lung protects against hyperoxic injury Am J Physiol Lung Cell Mol Physiol, June 1, 2004; 286(6): L1188 - L1193. [Abstract] [Full Text] [PDF]

				C. P. Rooney, G. M. Denning, B. P. Davis, D. M. Flaherty, J. A. Chiorini, and J. Zabner Bronchoalveolar Fluid Is Not a Major Hindrance to Virus-Mediated Gene Therapy in Cystic Fibrosis J. Virol., September 11, 2002; 76(20): 10437 - 10443. [Abstract] [Full Text] [PDF]